Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

... treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary ... in Japanese Patients with Paroxysmal nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study ... treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840-1847. ...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

... with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) independent of improvements ... treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) occurs independent of ... L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med ....

Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose

... Insomnia Middle-of-the-night (MOTN) or nocturnal awakenings have been reported to be one of the ... [in press], Maurice M. Ohayon, MD, DSc, PhD.), nocturnal awakenings are the most frequently reported ... MOTN insomnia. "The prevalence and impact of nocturnal awakenings may require significant adjustments in ...

Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008

... Night Awakenings Middle-of-the-night (MOTN) or nocturnal awakenings have been reported to be one of the ... (in press), Maurice M. Ohayon, MD, DSc, PhD.), nocturnal awakenings are the most frequently reported ... population report that their pattern of nocturnal awakenings persists for at least six months and ...

Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

... a treatment for Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The open-label study, which ... the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840-1847. (2) ... inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. ...

Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

... the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood First Edition. ... inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. ... The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in ...

PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity

... with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), including those who might ... Significant Disease Burden in Paroxysmal nocturnal Hemoglobinuria Patients with Lower Levels ... L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253- ...

Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH

... with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH) were found to be six times ... Renal Insufficiency in Patients with Paroxysmal nocturnal Hemoglobinuria (PNH)" and "Sustained Improvements ... with Eculizumab Treatment in Paroxysmal nocturnal Hemoglobinuria." Soliris, Hemolysis and PNH ...

Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients

... with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), according to an analysis of ... for the treatment of patients with paroxysmal nocturnal hemoglobinuria" reported data from the 97 ... L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med ...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

... ), is the first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and ... thromboembolism in patients with paroxysmal nocturnal hemoglobinuria," analyzed data from 195 patients ... al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:3699-3709. (3) ...

Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease

... criteria (greater than or equal to 30% improvement of UPDRS III score). nocturnal akinesia -- inability to move at night -- was reduced by 56%, and improvement was also noted in nocturnal dystonia -- painful muscle contraction -- and cramps. Neupro(R) improved ...

American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought

... with respect to components of the EPACs, or secondary outcomes including pulmonary function, airways reactivity, asthma control, symptom scores, nocturnal awakenings, or quality of life. GER documented by pH probe studies in 40% of participants with absent or minimal symptoms did not identify a subgroup ...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

... Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), was associated with an improvement in hematologic parameters in a limited number of patients with two other rare and severe ...

Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period

... diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R) DS for the relief of discomfort of the lower urinary tract. The Ferring Group specializes in the research, development ...

Nationwide Survey Shows Infertility Patients Prefer ENDOMETRIN(R) Compared With Other Progesterone Supplements

... diagnosis of Cushing's syndrome; and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric ...

Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody

... disorders. In March 2007, the FDA granted marketing approval for Alexion's first product, Soliris(R) (eculizumab), for all patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease. In June 2007, the European Commission granted marketing approval for ...

Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADA's Recommended Target for Blood Sugar Control

... may be serious. In the Lantus(R) arm of the TULIP trial, there were 4.2 +/- 6.6 (p<0.0001) cases of symptomatic, 0.7 +/- 2.1 (p=0.0011) cases of nocturnal and 0.04 +/- 0.35 (p=0.147) cases of severe hypoglycemia events reported per patient year. However, no patients dropped out of the trial due to ...

Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis

... diagnosis of Cushing's syndrome and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric ...

Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World

... diagnosis of Cushing's syndrome and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric ...

Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes

... (eculizumab), a new treatment for paroxysmal nocturnal hemoglobinuria (PNH) developed by ... is indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Alexion ... S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:3699-3709. (3) ...

Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients

... (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) at the 12th Congress of ... Reduces Thrombosis in Patients with Paroxysmal nocturnal Hemoglobinuria (PNH)," presented by Dr. Peter ... Inhibitor Eculizumab in Patients with Paroxysmal nocturnal Hemoglobinuria: SHEPHERD Phase III Clinical Study ...

Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease

... 92.8 0.014 (Primary endpoint) % time pH>4 nocturnal 96.3 90.3 0.0028 Total duration reflux ... duration reflux 16.2 48.6 0.0021 pH<4 nocturnal (min) No. symptomatic 1.9 7.0 ...

Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study

... was designed to demonstrate proof-of-concept for DDP733 as a treatment for nocturnal GERD (NGERD). The 0.5 mg dose of DDP733 achieved ... patents related to the use of DDP733 as a treatment for GERD. About nocturnal Gastroesophageal Reflux Disease (NGERD) Gastroesophageal reflux disease ...

Ferring Reports on ENDOMETRIN Presentations at Pacific Coast Reproductive Society Annual Meeting

... diagnosis of Cushing's syndrome and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, ...

DuoCort AB: DuoCort announces Phase I Data Presentation at the European Congress of Endocrinology

... Moreover, the data showed no risk of dose accumulation. The release profile closely resembled the physiological one, including the natural nocturnal cortisol free interval. Based on the promising Phase I data, DuoCort is now launching its Phase II / III program. "We are very pleased with the ...

Dynogen Reports Positive Results in Phase 1B GERD Study

... profiles. Dynogen has exclusive rights under issued U.S. and European patents related to the use of DDP733 as a treatment for GERD. About nocturnal Gastroesophageal Reflux Disease (NGERD) Gastroesophageal reflux disease (GERD) is a chronic condition that afflicts approximately 20 percent of ...